Industry news that matters to you.  Learn more

SciClips Launches Biomarker and Drug Discovery Protocols Database

SciClips is an open innovation platform that enables scientists and researchers to collaborate and share research and ideas. Following up on a diagnostic and prognostic biomarker database released earlier this year, SciClips has launched a second database constisting of biomarker and drug discovery research protocols.

Indiana CTSI, GVK Biosciences Partner to Provide National Access to Biomarkers Database

The Indiana Clinical and Translational Sciences Institute (CTSI), a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond, announced on Friday that they have partnered with GVK Biosciences. GVK Biosciences will provide researchers across the United States access to their clinical biomarker database.

Cleveland Clinic Selected as Site for Michael J. Fox Foundation Parkinson’s Disease Study

Cleveland Clinic has been selected as a site for the Parkinson’s Progression Markers Initiative (PPMI), a landmark five-year research study that aims to identify biomarkers of the disease. The study is sponsored by the Michael J. Fox Foundation.

Immunodepletion Followed by LC-MS/MS is Best for Serum-based Clinical Discovery Biomarkers

The discovery of human serum or plasma biomarkers is hindered by the presence of highly abundant proteins that may mask many low abundant species that have clinical value. A recent study in the journal Proteomics systematically compared immunodepletion of 6, 14 or 20 proteins using serum from renal transplant patients and analyzed reproducibility, depth of coverage, efficiency and specificity on two analytical platforms: 2-D differential gel electrophoresis (DIGE) (‘top-down’) and liquid chromatography tandem mass spectrometry (LC-MS/MS) (‘bottom-up’).

Fujirebio Diagnostics, Inc. Receives FDA 510(k) Clearance for First Biomarker to Monitor Lung Cancer

Fujirebio Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ EIA assay to monitor disease progression during the course of disease and treatment of lung cancer patients. This is the first biomarker assay kit to be cleared by FDA for use in the management of patients with lung cancer.